Perception of Improvement in Patients With Rheumatoid Arthritis Varies With Disease Activity Levels at Baseline

被引:60
作者
Aletaha, D. [1 ]
Funovits, J.
Ward, M. M. [2 ]
Smolen, J. S. [3 ]
Kvien, T. K. [4 ]
机构
[1] Med Univ Vienna, Dept Internal Med 3, Vienna, Austria
[2] NIAMSD, NIH, Bethesda, MD 20892 USA
[3] Hietzing Hosp, Vienna, Austria
[4] Diakonhiemet Hosp, Oslo, Norway
来源
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH | 2009年 / 61卷 / 03期
关键词
CLINICAL-TRIALS; OUTCOME MEASURES; SYMPTOM STATE; INDEXES; VALIDATION; VARIABLES; THERAPY; COUNTS;
D O I
10.1002/art.24282
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Objective. To analyze the minimum clinically important improvement (MCII) of disease activity measures in rheumatoid arthritis (RA) using patient-derived anchors, and to assess whether criteria for improvement differ with baseline disease activity. Methods. We used data from a Norwegian observational database comprising 1,050 patients (73% women, 65% rheumatoid factor-positive, mean duration of RA 7.7 years). At 3 months after initiation of therapy, patients indicated whether their condition had improved, had considerably improved, was unchanged, had worsened, or had considerably worsened. We used receiver operating characteristic curve analysis to determine the MCII for the Disease Activity Score based on the assessment of 28 joints (DAS28), the Simplified Disease Activity Index (SDAI), and the Clinical Disease Activity Index (CDAI), and analyzed the effects of different levels of baseline disease activity on the MCII. Results. On average, patients started with high disease activity and improved significantly during treatment (American College of Rheumatology 20%, 50%, and 70% improvement criteria responses were 37%, 17%, and 5%, respectively). The overall mean (95% confidence interval [95% CI]) thresholds for MCII after 3 months for the DAS28, SDAI, and CDAI were 1.20 (95% CI 1.18-1.22), 10.95 (95% CI 10.69-11.20), and 10.76 (95% CI 10.49-11.04), respectively, and the mean (95% CI) thresholds for major responses were 1.82 (95% Cl 1.80-1.83), 15.82 (95% Cl 15.65-16.00), and 15.00 (95% CI 14.82-15.18), respectively. With increasing disease activity, much higher changes in disease activity were needed to achieve MCII according to patient judgment. Conclusion. The perception of improvement of disease activity of patients with RA is considerably different depending on the disease activity level at which they start.
引用
收藏
页码:313 / 320
页数:8
相关论文
共 30 条
[1]
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations [J].
Aletaha, D. ;
Landewe, R. ;
Karonitsch, T. ;
Bathon, J. ;
Boers, M. ;
Bombardier, C. ;
Bombardieri, S. ;
Choi, H. ;
Combe, B. ;
Dougados, M. ;
Emery, P. ;
Gomez-Reino, J. ;
Keystone, E. ;
Koch, G. ;
Kvien, T. K. ;
Martin-Mola, E. ;
Matucci-Cerinic, M. ;
Michaud, K. ;
O'Dell, J. ;
Paulus, H. ;
Pincus, T. ;
Richards, P. ;
Simon, L. ;
Siegel, J. ;
Smolen, J. S. ;
Sokka, T. ;
Strand, V. ;
Tugwell, P. ;
van der Heijde, D. ;
van Riel, P. ;
Vlad, S. ;
van Vollenhoven, R. ;
Ward, M. ;
Weinblatt, M. ;
Wells, G. ;
White, B. ;
Wolfe, F. ;
Zhang, B. ;
Zink, A. ;
Felson, D. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (10) :1360-1364
[2]
Reporting Disease Activity in Clinical Trials of Patients With Rheumatoid Arthritis: EULAR/ACR Collaborative Recommendations [J].
Aletaha, D. ;
Landewe, R. ;
Karonitsch, T. ;
Bathon, J. ;
Boers, M. ;
Bombardier, C. ;
Bombardieri, S. ;
Choi, H. ;
Combe, B. ;
Dougados, M. ;
Emery, P. ;
Gomez-Reino, J. ;
Keystone, E. ;
Koch, G. ;
Kvien, T. K. ;
Martin-Mola, E. ;
Matucci-Cerinic, M. ;
Michaud, K. ;
O'Dell, J. ;
Paulus, H. ;
Pincus, T. ;
Richards, P. ;
Simon, L. ;
Siegel, J. ;
Smolen, J. S. ;
Sokka, T. ;
Strand, V. ;
Tugwell, P. ;
van der Heijde, D. ;
van Riel, P. ;
Vlad, S. ;
van Vollenhoven, R. ;
Ward, M. ;
Weinblatt, M. ;
Wells, G. ;
White, B. ;
Wolfe, F. ;
Zhang, B. ;
Zink, A. ;
Felson, D. .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2008, 59 (10) :1371-1377
[3]
Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score [J].
Aletaha, D ;
Nell, VP ;
Stamm, T ;
Uffmann, M ;
Pflugbeil, S ;
Machold, K ;
Smolen, JS .
ARTHRITIS RESEARCH & THERAPY, 2005, 7 (04) :R796-R806
[4]
The importance of reporting disease activity states in rheumatoid arthritis clinical trials [J].
Aletaha, Daniel ;
Funovits, Julia ;
Smolen, Josef S. .
ARTHRITIS AND RHEUMATISM, 2008, 58 (09) :2622-2631
[5]
Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients [J].
Aletaha, Daniel ;
Funovits, Julia ;
Keystone, Edward C. ;
Smolen, Josef S. .
ARTHRITIS AND RHEUMATISM, 2007, 56 (10) :3226-3235
[6]
Measuring function in rheumatoid arthritis - Identifying reversible and irreversible components [J].
Aletaha, Daniel ;
Smolen, Josef ;
Ward, Michael M. .
ARTHRITIS AND RHEUMATISM, 2006, 54 (09) :2784-2792
[7]
BOMBARDIER C, 1982, J RHEUMATOL, V9, P753
[8]
Bootstrapping: estimating confidence intervals for cost-effectiveness ratios [J].
Campbell, MK ;
Torgerson, DJ .
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 1999, 92 (03) :177-182
[9]
A proposed revision to the ACR20:: The hybrid measure of American College of Rheumatology response [J].
Felson, David ;
Aletaha, Daniel ;
Anderson, Jennifer ;
Bathon, Joan ;
Boers, Maarten ;
Bombardier, Claire ;
Choi, Hyon ;
Dougados, Maxine ;
Furst, Dan ;
Koch, Gary ;
Landewe, Robert ;
LaValley, Mike ;
Michaud, Kaleb ;
Paulus, Hal ;
Pincus, Theodore ;
Siegel, Jeffrey ;
Simon, Lee ;
Smolen, Josef ;
Tugwell, Peter ;
van der Heijde, Desiree ;
White, Barbara ;
Wolfe, Fred ;
Xie, Hui .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2007, 57 (02) :193-202
[10]
THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY PRELIMINARY CORE SET OF DISEASE-ACTIVITY MEASURES FOR RHEUMATOID-ARTHRITIS CLINICAL-TRIALS [J].
FELSON, DT ;
ANDERSON, JJ ;
BOERS, M ;
BOMBARDIER, C ;
CHERNOFF, M ;
FRIED, B ;
FURST, D ;
GOLDSMITH, C ;
KIESZAK, S ;
LIGHTFOOT, R ;
PAULUS, H ;
TUGWELL, P ;
WEINBLATT, M ;
WIDMARK, R ;
WILLIAMS, HJ ;
WOLFE, F .
ARTHRITIS AND RHEUMATISM, 1993, 36 (06) :729-740